Почетна › Трипл негативен рак на дојка › Тексас › San Antonio
Клинички испитувања за Трипл негативен рак на дојка во San Antonio, TX
23 студии за Трипл негативен рак на дојка бараат учесници на локации во и околу San Antonio (во радиус од околу 30 милји). Отворете ја студијата за да видите кој може да учествува и како да го контактирате тимот.
Официјален текст на студијата (англиски)
Барате учесници за студија? Истакнете ја на врвот од оваа страница — $99 за 30 дена →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Се регрутираФаза 1
- South Texas Accelerated Research Therapeutics (START), San Antonio
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Се регрутираФаза 1/2
- New Experimental Therapeutics of San Antonio - NEXT Oncology, San Antonio
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
Се регрутираФаза 1/2
- NEXT Oncology, San Antonio
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Се регрутираФаза 3
- Texas Oncology - San Antonio ( Site 8001), San Antonio
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Се регрутираФаза 3
- Mays Cancer Center ( Site 0122), San Antonio
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Се регрутираФаза 3
- Texas Oncology - San Antonio ( Site 8004), San Antonio
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
Се регрутираФаза 1
- NEXT Oncology, San Antonio
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Се регрутираФаза 1/2
- NEXT Oncology - San Antonio, San Antonio
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Се регрутираФаза 3
- Texas Oncology, San Antonio
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Се регрутираФаза 1
- South Texas Accelerated Research Therapeutics (START) San Antonio, San Antonio
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
Се регрутираФаза 1
- START-San Antonio, San Antonio
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Се регрутираФаза 1/2
- Research Site, San Antonio
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Се регрутираФаза 1
- Normunity Investigational Site, San Antonio
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Се регрутираФаза 1/2
- START San Antonio, San Antonio
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
Се регрутираФаза 1/2
- Clinical Trial Site, San Antonio
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Се регрутираФаза 1
- NEXT Virginia, LLC, San Antonio
- South Texas Accelerated Research Therapeutics, LLC, San Antonio
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Се регрутираФаза 1
- START San Antonio, San Antonio
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Се регрутираФаза 1
- NEXT Oncology /ID# 243007, San Antonio
- South Texas Accelerated Research Therapeutics (START) /ID# 276268, San Antonio
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Се регрутираФаза 1
- NEXT Texas LLC - San Antonio, San Antonio
- START San Antonio, LLC, San Antonio
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Се регрутираФаза 1
- NEXT Oncology, San Antonio
PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer
Се регрутираФаза 1
- NEXT Oncology, San Antonio
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Се регрутираФаза 1
- Dren Investigational Site, San Antonio
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Се регрутираФаза 2
- Texas Oncology PA (San Antonio), San Antonio
Испитувања за Трипл негативен рак на дојка во други градови
- Houston, TX42 студии
- New York City, NY31 студија
- Nashville, TN28 студии
- Los Angeles, CA27 студии
- Boston, MA26 студии
- St. Louis, MO21 студија
- Arlington, VA20 студии
- Atlanta, GA20 студии
- Dallas, TX18 студии
- Chicago, IL16 студии
- Columbus, OH16 студии
- Grand Rapids, MI15 студии
Други студии во San Antonio
- Рак на бели дробови со не-мали клетки59 студии
- Рак на дојка47 студии
- Колоректален карцином46 студии
- Метастатски карцином44 студии
- Рак (сите типови)41 студија
- Дебелина40 студии
- Дијабетес тип 237 студии
- Прекумерна телесна тежина34 студии
- Карцином на јајниците31 студија
- Карцином на панкреасот31 студија
- Рак на простата28 студии
- Рак на ендометриумот27 студии
Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.